Catalyst Pharmaceuticals, Inc. raised revenue guidance for the full year 2023. For the year, the company expects total revenues, including FYCOMPA, to be between $390 million and $395 million, representing an 82% to 84% increase in total revenues compared to 2022. Key guidance assumptions in this forecast reflect a continued recovery in macroeconomic and healthcare activity throughout 2023 related to the current COVID-19 environment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.53 USD | -2.30% | +0.24% | -1.67% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.67% | 1.95B | |
-2.99% | 89.49B | |
+2.50% | 40.67B | |
-12.01% | 33.15B | |
+62.74% | 26.45B | |
-19.79% | 14.69B | |
-8.58% | 12.89B | |
-12.34% | 11.54B | |
-43.92% | 11.34B | |
+3.75% | 8.84B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023